3차 병원에서 신기능에 따른 에녹사파린 용량의 적절성 분석

Abstract

Abstract Enoxaparin, Low-molecular-weight heparin (LMWH), is an anticoagulant drug mostly used to prevent and treat venous thromboembolism compared to other LMWHs such as dalteparin, fondaparinux and nadroparin etc. The recent studies have shown that the patients with renal dysfunction frequently occur the accumulation of enoxaparin in the body, which leads to increase bleeding tendency. However, in Korea, there is little recommended guideline regarding the dosing of enoxaparin for the prophylaxis and treatment of venous thromboembolism for patients with renal impairment as well as related studies have rarely been conducted. The aim of this study was to examine the appropriateness of enoxaparin dosing by patients' renal function in a tertiary hospital. This study was retrospectively conducted through Electronic Medical Record (EMR) which contained laboratory data and enoxaparin dosing of each patients. 801 out of total 830 patients were selected based on inclusion criteria and classified by renal function in this study. As a result, 73.3% of the patients with severe renal dysfunction (Creatinine clearance<30ml/min) were given inappropriate, high dose of enoxaparin, especially in case of the prophylaxis venous thromboembolism. In addition, further studies associated with enoxaparin renal dosing and related anticoagulation parameters, recently suggested by ACCP are requested.